Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria

PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 18, 2014

Primary Completion Date

November 23, 2016

Study Completion Date

April 30, 2017

Conditions
Malaria, Vivax
Interventions
DRUG

Eurartesim tablets

dosage bands: 24 to \<36 kg body weight: 2 tablets a day for three consecutive days 36 to \<75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days

Trial Locations (13)

20157

Azienda ospedaliera Luigi Sacco, Milan

42123

Azienda Ospedaliera Arcispedale S. Maria Nuova IRCCS - Dip. Medicina Interna e Spec. Mediche, Reggio Emilia

Unknown

Hôpital St André-CHU, Médecine interne et Maladies tropicales, Bordeaux

Medizinische Klinik mit Schwerpunkt Infektiologie, Charite/Campus Virchow-Klinikum, Berlin

Department of Infectious Diseases & Tropical Medicine, University of Munich, Munich

15. The Center for Geographic Medicine and Tropical Diseases, Department of Medicine C - The Chaim Sheba Medical Center, Tel Litwinsky

Clinica di Malattie Infettive e Tropicali, Universitá di Brescia, Brescia

Centro di Malattie Tropicali - INMI Spallanzani, Roma

Dep. Infectious Disease, Section Travel Medicine, Leiden University Medical Centre, Leiden

CRESIB-Hospital Clinic, Barcelona, Barcelona

Hospital Vall d'Hebron, Barcelona, Barcelona

Medical and Diagnostic Service Department, Swiss Tropical and Public Health Institute, Basel

Bern University Hospital, Bern

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alfasigma S.p.A.

INDUSTRY

NCT02110784 - Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria | Biotech Hunter | Biotech Hunter